CTLA4 and pneumonitis: CTLA‐4 inhibitor treatment alone did not seem to increase the incidence of pneumonitis, but the incidence of CIP increased when CTLA‐4 inhibitor was combined with PD‐1/PD‐L1 inhibitor.